Inada M, Crowl R M, Bekkers A C, Verheij H, Weiss J
Department of Microbiology, New York University School of Medicine, New York 10016.
J Biol Chem. 1994 Oct 21;269(42):26338-43.
It has been suggested (Kini, R. R., and Evans, H. J. (1987) J. Biol. Chem. 262, 14402-14407) that the anticoagulant activity of members of the 14-kDa phospholipase A2 (PLA2) family depends on the presence of basic residues within a variable surface region (residues 54-77) distinct from both the conserved catalytic machinery and surface sites mediating the antibacterial action of these enzymes (see Weiss, J., Inada, M., Elsbach, P., and Crowl, R. M. (1994) J. Biol. Chem. 269, 26331-26337). To further define the determinants of the anticoagulant activity of PLA2, we have analyzed the inhibitory effects of purified native and recombinant PLA2 on cell-free prothrombinase. Both native and recombinant wild-type pig pancreas (net charge -1) and human "secretory" PLA2 (net charge +15) produced similar dose-dependent inhibition of prothrombinase activity that was significantly less potent than a toxic PLA2 purified from snake venom. Site-specific mutations that either increased or decreased PLA2 activity toward bactericidal/permeability-increasing protein-treated Escherichia coli by up to 50-fold had no effect on antiprothrombinase activity. In contrast, substitution of Arg for Asp-59/Gly for Ser-60 in the pig PLA2 increased antiprothrombinase activity by 5-10-fold without affecting catalytic activity toward a range of phospholipid substrates or antibacterial activity. Comparison of antiprothrombinase activity of catalytically active and inactive forms of the PLA2 and under a range of phospholipid conditions revealed that the potent antiprothrombinase activity of native toxic venom PLA2 and of the D59R.S60G mutant pancreatic PLA2 reflect combined catalytic and noncatalytic actions, the latter apparently dependent on basic residues at discrete surface sites in the enzyme.
有人提出(基尼,R.R.,和埃文斯,H.J.(1987年)《生物化学杂志》262卷,14402 - 14407页),14 kDa磷脂酶A2(PLA2)家族成员的抗凝活性取决于可变表面区域(54 - 77位氨基酸残基)内碱性残基的存在,该区域与保守的催化机制以及介导这些酶抗菌作用的表面位点均不同(见魏斯,J.,稻田,M.,埃尔兹巴赫,P.,和克劳尔,R.M.(1994年)《生物化学杂志》269卷,26331 - 26337页)。为了进一步确定PLA2抗凝活性的决定因素,我们分析了纯化的天然和重组PLA2对无细胞凝血酶原酶的抑制作用。天然和重组的野生型猪胰腺PLA2(净电荷 -1)和人“分泌型”PLA2(净电荷 +15)对凝血酶原酶活性产生了相似的剂量依赖性抑制,其效力明显低于从蛇毒中纯化的有毒PLA2。使PLA2对经杀菌/通透性增加蛋白处理的大肠杆菌的活性增加或降低高达50倍的位点特异性突变,对抗凝血酶原酶活性没有影响。相反,猪PLA2中用精氨酸替代天冬氨酸 - 59/用丝氨酸替代甘氨酸 - 60,使抗凝血酶原酶活性提高了5 - 10倍,而不影响对一系列磷脂底物的催化活性或抗菌活性。在一系列磷脂条件下,对PLA2的催化活性和无活性形式的抗凝血酶原酶活性进行比较,结果表明,天然有毒蛇毒PLA2和D59R.S60G突变型胰腺PLA2的强效抗凝血酶原酶活性反映了催化作用和非催化作用的结合,后者显然依赖于酶中离散表面位点的碱性残基。